false 0001427925 0001427925 2023-06-15 2023-06-15
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 15, 2023
 
 
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
  
001-35068
  
41-2193603
(State of incorporation)
  
(Commission File No.)
  
(IRS Employer Identification No.)
 
25821 Industrial Blvd, Suite 400
Hayward, CA 94545
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: (650) 216-3500
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act
 
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
ACRX
The Nasdaq Global Market
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 8.01. Other Events. 
 
As previously disclosed by AcelRx Pharmaceuticals, Inc. (the “Company”) in its filings with the U.S. Securities and Exchange Commission, the Company had received a letter from The Nasdaq Stock Market LLC ("Nasdaq") on April 26, 2023 notifying the Company of its non-compliance the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market.
 
On June 15, 2023, the Company received notice from Nasdaq confirming that the Company has cured its bid price deficiency and has regained compliance with the Minimum Bid Price Rule, and that this matter is now closed.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: June 15, 2023
ACELRX PHARMACEUTICALS, INC.
     
 
By:
/s/ Raffi Asadorian
   
Raffi Asadorian
   
Chief Financial Officer
 
 
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more AcelRX Pharmaceuticals Charts.
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more AcelRX Pharmaceuticals Charts.